C4 Therapeutics (CCCC) Cash from Operations (2019 - 2025)
Historic Cash from Operations for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$31.2 million.
- C4 Therapeutics' Cash from Operations fell 2931.26% to -$31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.8 million, marking a year-over-year decrease of 6808.84%. This contributed to the annual value of -$65.2 million for FY2024, which is 3901.33% up from last year.
- As of Q3 2025, C4 Therapeutics' Cash from Operations stood at -$31.2 million, which was down 2931.26% from -$12.1 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Cash from Operations ranged from a high of -$5.0 million in Q2 2024 and a low of -$33.3 million during Q1 2025
- For the 5-year period, C4 Therapeutics' Cash from Operations averaged around -$23.2 million, with its median value being -$24.1 million (2024).
- Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 7381.69% in 2024, then tumbled by 14240.05% in 2025.
- Quarter analysis of 5 years shows C4 Therapeutics' Cash from Operations stood at -$25.7 million in 2021, then fell by 13.47% to -$29.1 million in 2022, then grew by 17.57% to -$24.0 million in 2023, then increased by 25.31% to -$17.9 million in 2024, then plummeted by 74.03% to -$31.2 million in 2025.
- Its Cash from Operations was -$31.2 million in Q3 2025, compared to -$12.1 million in Q2 2025 and -$33.3 million in Q1 2025.